{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "exchange": "FRA", "shortName": "TRANSGENE SA  EO 0,50", "longName": "Transgene SA", "messageBoardId": "finmb_386045", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketChangePercent": -1.1173174, "regularMarketPrice": 1.77, "marketState": "REGULAR", "fiftyTwoWeekHighChangePercent": -0.31528047, "fiftyTwoWeekLow": 1.548, "fiftyTwoWeekHigh": 2.585, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.33, "sharesOutstanding": 100204000, "bookValue": 0.379, "fiftyDayAverage": 1.88538, "fiftyDayAverageChange": -0.11538005, "fiftyDayAverageChangePercent": -0.061197236, "twoHundredDayAverage": 1.90073, "twoHundredDayAverageChange": -0.13073003, "twoHundredDayAverageChangePercent": -0.06877886, "marketCap": 177361072, "priceToBook": 4.6701846, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "priceHint": 4, "regularMarketChange": -0.01999998, "regularMarketTime": 1683871387, "regularMarketDayHigh": 1.77, "regularMarketDayRange": "1.77 - 1.77", "regularMarketDayLow": 1.77, "regularMarketVolume": 2003, "regularMarketPreviousClose": 1.79, "bid": 1.726, "ask": 1.8, "bidSize": 1223, "askSize": 1200, "fullExchangeName": "Frankfurt", "financialCurrency": "EUR", "regularMarketOpen": 1.77, "averageDailyVolume3Month": 34, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 0.222, "fiftyTwoWeekLowChangePercent": 0.14341086, "fiftyTwoWeekRange": "1.548 - 2.585", "fiftyTwoWeekHighChange": -0.81500006, "firstTradeDateMilliseconds": 957333600000, "symbol": "TGNA.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "400, boulevard Gonthier d\u2019Andernach", "address2": "Parc d\u2019innovation CS80166 Cedex", "city": "Illkirch-Graffenstaden", "zip": "67405", "country": "France", "phone": "33 3 88 27 91 00", "fax": "33 3 88 27 91 11", "website": "https://www.transgene.fr", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Merck & Co, Sanofi, BioInvent, and Randox. Transgene SA was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.", "fullTimeEmployees": 146, "companyOfficers": [{"maxAge": 1, "name": "Mr. Hedi Ben Brahim", "age": 41, "title": "CEO & Director", "yearBorn": 1981, "fiscalYear": 2022, "totalPay": {"raw": 315000, "fmt": "315k", "longFmt": "315,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jean-Philippe  Del", "age": 41, "title": "VP & CFO", "yearBorn": 1981, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Eric  Quemeneur Ph.D.", "age": 57, "title": "Exec. VP & Chief Scientific Officer", "yearBorn": 1965, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Elisabetta  Castelli", "title": "Director of Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. John  Felitti J.D., LLM", "age": 52, "title": "VP, Gen. Counsel & Corp. Sec.", "yearBorn": 1970, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Lucie  Larguier", "title": "Director of Corp. Communications & IR", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Gaelle  Stadtler", "age": 39, "title": "VP & Director of HR", "yearBorn": 1983, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Maud  Brandely-Talbot M.D., Ph.D.", "age": 68, "title": "VP of Medical Affairs & Chief Medical Officer", "yearBorn": 1954, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Steven H. Bloom R.Ph.", "age": 60, "title": "VP & Chief Bus. Officer", "yearBorn": 1962, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Kaidre  Bendjama", "title": "Project Leader of Personalized Cancer Vaccines", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}